Trastuzumab Emtansine plus Pertuzumab Versus Taxane plus Trastuzumab plus Pertuzumab after Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study

Trastuzumab Emtansine plus Pertuzumab Versus Taxane plus Trastuzumab plus Pertuzumab after Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study

PURPOSE We aimed to improve efficacy and reduce toxicity of high-risk human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (EBC) treatment by replacing taxanes and trastuzumab with trastuzumab emtansine (T-DM1). METHODS The phase III KAITLIN study (NCT01966471) included adult...

Full description

Bibliographic Details
Main Authors: Barrios, C. (Author), Bonnefoi, H. (Author), Boulet, T. (Author), De Laurentiis, M. (Author), Ellis, P.A (Author), Fehrenbacher, L. (Author), Gianni, L. (Author), Gralow, J. (Author), Harbeck, N. (Author), Huang, C.-S (Author), Im, S.-A (Author), Im, Y.-H (Author), Ito, Y. (Author), Krop, I.E (Author), Liu, H. (Author), Macharia, H. (Author), Nowecki, Z. (Author), Shah, J. (Author), Song, C. (Author), Swain, S.M (Author), Toi, M. (Author), Trask, P. (Author), Winer, E.P (Author)
Format: Article
Language:English
Published: American Society of Clinical Oncology 2022
Subjects:
adjuvant chemotherapy
Ado-Trastuzumab Emtansine
adult
Adult
aged
Aged
anthracycline
Anthracyclines
Antibiotics, Antineoplastic
Antibodies, Monoclonal, Humanized
antineoplastic agent
antineoplastic antibiotic
Antineoplastic Combined Chemotherapy Protocols
Breast Neoplasms
breast tumor
Chemotherapy, Adjuvant
clinical trial
comparative study
controlled study
disease free survival
Disease-Free Survival
enzymology
epidermal growth factor receptor 2
ERBB2 protein, human
female
Female
human
Humans
metabolism
middle aged
Middle Aged
monoclonal antibody
multicenter study
pathology
pertuzumab
phase 3 clinical trial
randomized controlled trial
Receptor, ErbB-2
time factor
Time Factors
trastuzumab
Trastuzumab
trastuzumab emtansine
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items